Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 2315Neoplasms 1678Prostatic Neoplasms 1178Lung Neoplasms 908Colorectal Neoplasms 873Carcinoma, Non-Small-Cell Lung 848Leukemia, Myeloid, Acute 587Pancreatic Neoplasms 568Multiple Myeloma 542Carcinoma, Hepatocellular 510Brain Neoplasms 509Neoplasm Metastasis 456Head and Neck Neoplasms 454Melanoma 410Ovarian Neoplasms 404Glioblastoma 397Precursor Cell Lymphoblastic Leukemia-Lymphoma 390Stomach Neoplasms 370Uterine Cervical Neoplasms 355Squamous Cell Carcinoma of Head and Neck 355Rectal Neoplasms 336Recurrence 332Hematologic Neoplasms 323Sarcoma 322Colonic Neoplasms 316Lymphoma 310Triple Negative Breast Neoplasms 284Urinary Bladder Neoplasms 279Glioma 277Carcinoma, Renal Cell 277

Interventions

Leucovorin 2Irinotecan 2Fluorouracil 2spartalizumab 1Radiosurgery 1Oxaliplatin 1Oncolytic Virotherapy 1IFL protocol 1Folfox protocol 1Drug Therapy 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × CRC × 1 year × Clear all
NCT03336658 2026-05-05

ITB

Insel Gruppe AG, University Hospital Bern

Completed
150 enrolled

CRC

NCT07381309 2026-04-28

VVSHIP

Sixth Affiliated Hospital, Sun Yat-sen University

Phase 2 Not yet recruiting
114 enrolled
Gastrointestinal

CRC

NCT07204574 2025-10-02

The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer

Chang Gung Memorial Hospital

Phase 1/2 Recruiting
40 enrolled

CRC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡